Hiroshi Moro

Associate Professor

Niigata University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Hiroshi Moro is an Associate Professor at Niigata University in Japan. His research focuses on infectious diseases and microbiology, with recent publications addressing topics such as iron metabolism in bloodstream infections, the prevention of sexually transmitted infections, and the evaluation of diagnostic kits for fungal infections. His work contributes to the understanding of bacterial profiles in pneumonia and factors affecting patients with rheumatic diseases.

Articles (10)

Year:

2026

Year:

2026

Year:

2025

Background Bacterial sexually transmitted infections (STIs) like syphilis, chlamydia and gonorrhoea are often asymptomatic but can cause severe complications, including infertility and vertical transmission in cisgender women, particularly female sex workers (FSWs). Sex work is strongly associated with syphilis, with FSWs representing 38% of syphilis cases among Japanese women in 2021. Despite doxycycline’s proven effectiveness in preventing bacterial STIs, its efficacy in high-risk cisgender women remains inconclusive, highlighting the need for targeted STI prevention strategies in this population. Objectives We investigated the effectiveness of doxycycline pre-exposure prophylaxis (doxyPrEP) in preventing STIs and its impact on vaginal flora among FSWs. Participants and methods This retrospective study included 40 FSWs aged ≥18 years who initiated doxyPrEP (100 mg/day) for STI prevention at a private clinic in Tokyo, Japan, between 1 October 2022 and 14 November 2023. Incidence rate ratios (IRR) for chlamydia, gonorrhoea, syphilis, bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC) were estimated using fixed-effects Poisson regression models. Adherence, side effects, and satisfaction were evaluated through follow-up clinical evaluations. Results Overall STI incidence significantly declined from 232.3 to 79.2/100 person-years following doxyPrEP initiation (IRR = 0.33, P = 0.020). The reduction in chlamydia showed marginal statistical significance (IRR = 0.35, P = 0.056), and syphilis cases dropped to zero. Gonorrhoea, BV, and VVC incidence showed no significant changes. Follow-up clinical evaluations indicated high adherence to doxyPrEP, no serious adverse events, and high satisfaction with doxyPrEP. Conclusions DoxyPrEP significantly reduced the overall STI incidence among FSWs without increasing other vaginal infections.

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Naokatsu Ando

National Center For Global Health and Medicine

JAPAN
View details

Yuuki Bamba

Assistant Professor

Niigata University Medical and Dental Hospital

JAPAN
View details